Africa Health Research Institute (AHRI), Durban, South Africa.
HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Nat Commun. 2022 Jul 12;13(1):4041. doi: 10.1038/s41467-022-31692-8.
HIV persistence in tissue sites despite ART is a major barrier to HIV cure. Detailed studies of HIV-infected cells and immune responses in native lymph node tissue environment is critical for gaining insight into immune mechanisms impacting HIV persistence and clearance in tissue sanctuary sites. We compared HIV persistence and HIV-specific T cell responses in lymph node biopsies obtained from 14 individuals who initiated therapy in Fiebig stages I/II, 5 persons treated in Fiebig stages III-V and 17 late treated individuals who initiated ART in Fiebig VI and beyond. Using multicolor immunofluorescence staining and in situ hybridization, we detect HIV RNA and/or protein in 12 of 14 Fiebig I/II treated persons on suppressive therapy for 1 to 55 months, and in late treated persons with persistent antigens. CXCR3 T follicular helper cells harbor the greatest amounts of gag mRNA transcripts. Notably, HIV-specific CD8 T cells responses are associated with lower HIV antigen burden, suggesting that these responses may contribute to HIV suppression in lymph nodes during therapy. These results reveal HIV persistence despite the initiation of ART in hyperacute infection and highlight the contribution of virus-specific responses to HIV suppression in tissue sanctuaries during suppressive ART.
尽管接受了抗逆转录病毒疗法(ART),但组织中的 HIV 持续存在仍是 HIV 治愈的主要障碍。对天然淋巴结组织环境中受感染的细胞和免疫反应进行详细研究,对于深入了解影响组织避难所中 HIV 持续存在和清除的免疫机制至关重要。我们比较了 14 名在 Fiebig 分期 I/II 开始治疗的个体、5 名在 Fiebig 分期 III-V 接受治疗的个体和 17 名在 Fiebig VI 及以后开始接受 ART 的晚期治疗个体的淋巴结活检中 HIV 持续存在和 HIV 特异性 T 细胞反应。通过多色免疫荧光染色和原位杂交,我们在 14 名接受抑制性治疗 1 至 55 个月的 Fiebig I/II 治疗者中的 12 名和持续存在抗原的晚期治疗者中检测到 HIV RNA 和/或蛋白。CXCR3 T 滤泡辅助细胞携带最多的 gag mRNA 转录本。值得注意的是,HIV 特异性 CD8 T 细胞反应与较低的 HIV 抗原负担相关,这表明这些反应可能有助于治疗期间淋巴结中的 HIV 抑制。这些结果揭示了尽管在超急性感染中开始了 ART,但 HIV 仍持续存在,并强调了病毒特异性反应对抑制性 ART 期间组织避难所中 HIV 抑制的贡献。
Front Immunol. 2018-1-25
Sci Transl Med. 2019-5-22
Microorganisms. 2025-2-18
Nat Rev Microbiol. 2024-6
AIDS Res Hum Retroviruses. 2023-12-13
Front Microbiol. 2019-10-1
Lancet Glob Health. 2019-11
J Clin Invest. 2019-7-30
Sci Transl Med. 2019-5-22
J Acquir Immune Defic Syndr. 2018-10-1